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ABSTRACT 
Vascular smooth muscle cells (vSMCs) are key in the regulation of blood pressure and 
the engagement of vascular pathologies such as hypertension, arterial remodeling, and 
neointima formation. The role of the Rac1 GTPase in these cells remains poorly 
characterized. To clarify this issue, we have utilized genetically engineered mice to 
manipulate the signaling output of Rac1 in these cells at will using inducible, Cre-
loxP-mediated DNA recombination techniques. Here, we show that the expression of 
an active version of the Rac1 activator Vav2 exclusively in vSMCs leads to 
hypotension as well as the elimination of the hypertension induced by the systemic loss 
of wild type Vav2. Conversely, the specific depletion of Rac1 in vSMCs causes 
defective nitric oxide vasodilation responses and hypertension.  Rac1, but not Vav2, is 
also important for neointima formation but not for hypertension-driven vascular 
remodeling. These animals have also allowed us to dismiss ethiological connections 
between hypertension and metabolic disease and, most importantly, identify 
pathophysiological programs that cooperate in the development and consolidation of 
hypertensive states caused by local vascular tone dysfunctions. Finally, our results 
suggest that the therapeutic inhibition of Rac1 will be probably associated with 
extensive cardiovascular-related side effects and identify pharmacological avenues to 
circumvent them. 
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INTRODUCTION 
The dynamic regulation of the contractile behavior of vSMCs is one of the main 
mechanisms used by organisms to maintain blood pressure levels under both physiological 
and hypertensive conditions (1). Vasoconstriction is primarily mediated by pressor 
molecules such as angiotensin II (AngII), catecholamines, endothelins, and eicosanoids.  
Upon binding to their specific G-protein coupled receptors, these stimuli promote the 
activation of phospholipase C-β-dependent pathways that, via the elevation of the 
intracellular Ca2+ concentration, favor the stimulation of the myosin light chain (MLC) 
kinase. This protein, in turn, induces vSMC contractility via MLC phosphorylation (1) (see 
scheme in Fig. 4A, dark red color pathway). Vasoconstrictor G-protein coupled receptors 
consolidate this process through inactivation of the negative regulatory MLC phosphatase. 
This requires the activation of the GTPase RhoA, the subsequent stimulation of Rho-
associated protein kinase (Rock) and, finally, the Rock-dependent inactivation of MLC 
phosphatase by transphosphorylation (1) (see scheme in Fig. 4A, light red color pathway). 
When required, vasodilation can be actively promoted by a number of extracellular ligands 
that antagonize vasoconstriction-promoting routes in vSMCs. One of the main stimuli 
involved in such response is nitric oxide (NO) (2), a gas produced by vascular endothelial 
cells. Upon diffusion into neighboring vSMCs, NO promotes the direct stimulation of 
soluble guanylate cyclase, cGMP production, and the cGMP-dependent activation of 
protein kinase G1 (also known as cGMP kinase I). This kinase eventually inactivates 
actomyosin contractility through the direct, phosphorylation-mediated inactivation of RhoA 
(2-4) (see below, Fig. 4A, dark blue color pathway). The signal output of this pathway is 
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further fine-tuned by the hydrolysis of cGMP into GMP by phosphodiesterase type 5 (5) 
(see below, Fig. 4A). In addition to blood pressure control, vSMC participate in a variety of 
vascular-related processes, including the development of hypertension-dependent and 
independent pathological states such as cardiovascular remodeling and neointima formation 
(1). 
 RhoA belongs to a large GTPase subfamily that includes, among many others, the 
widely characterized Rac1 and Cdc42 proteins (6, 7). With the notable exception of RhoA, 
the role of other Rho subfamily GTPases in vSMCs remains poorly characterized (1). The 
function of Rac1 is particularly unsettled, since available data support its implication in 
both vasoconstriction (8-10) and vasodilation (11, 12). In favor of the latter role, we have 
recently reported using knockout mice for Vav2, a phosphorylation-dependent GDP/GTP 
exchange factor involved in the activation step of Rho family GTPases (13-15), the 
presence of a NO-Src-Vav2-Rac1-p21 activated kinase signaling pathway in vSMCs that 
favors vasodilation responses through the p21 activated kinase-dependent inactivation of 
phosphodiesterase type 5 (see scheme in Fig. 4A, light blue pathway) (11). The 
contradictory roles reported for Rac1 in the contractility behavior of vSMCs can be 
explained if it triggers different signaling responses depending on the extracellular stimuli 
and upstream exchange factors engaged. However, since most of the aforementioned 
studies have been done using overexpression methods in cultured vSMCs, it is also possible 
that some of the Rac1-dependent functions previously reported could be the result of 
exacerbated, nonphysiological effects elicited by those ectopically expressed mutants 
and/or the result of their interference with parallel, Rho GTPase-dependent routes. On the 
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other hand, it can be also argued that the results obtained in Vav2–/– mice may derive from 
concurrent signaling defects present in other cell types. There is more agreement regarding 
the implication of Rac1 in vSMC-dependent pathological processes such as hypertension-
driven arterial remodeling and neointima formation (1, 10, 16). However, since these data 
have been obtained using ectopically expressed dominant negative and constitutively active 
Rac1 mutants, is still unknown whether they accurately reflect the role of endogenous Rac1 
in these processes. To clarify the specific roles of Rac1-dependent routes vSMCs, we 
decided to utilize a number of genetically manipulated mice to evaluate the short- and long-
term effects that the in vivo manipulation of the signaling output of Rac1 and Vav family 
proteins in vSMCs induced in vascular tone, blood pressure, and a number of vessel-
associated pathologies. In addition, we used these animals as tools to address related 
questions in the field such as the characterization of the impact that these intrinsic vSMC 
changes induce in systemic physiological circuits traditionally associated with hypertensive 
states. 
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MATERIALS AND METHODS 
Animals 
The basal OncoVav2 mouse strain was custom-made (GenOway) and maintained in a 
mixed C57BL/6-129SV (75%-25%) genetic background.  Vav2–/–, Vav3–/–, Vav2–/–;Vav3–/–, 
Rac1flox/flox, and Cdc42flox/flox mice have been described before (17-20). These mice were in a 
pure C57BL/10 genetic background (Vav family knockout mice) or in mixed 
129SV4/SVjae-Balb/C-C57BL/6 (Rac1flox/flox mice) and C57BL/6-129SV (Cdc42flox/flox) 
genetic backgrounds. To generate the inducible, vSMC-specific strains, basal OncoVav2, 
Rac1flox/flox, and Cdc42flo/flox mice were individually crossed with the Myh11-Cre-ERT2 
transgenic line (C57/BL6 genetic background) (21).  The genetic background of the 
resulting compound lines was not homogenized.  The constitutive OncoVav2 mouse strain 
was generated by crossing the basal strain with transgenic mice expressing a constitutively 
expressed Cre (GenOway).  These mice were maintained in a mixed C57BL/6-129SV 
(75%-25%) genetic background.  All animals were kept in the pathogen-free and quarantine 
area of the University of Salamanca and Max-Planck Institute for Heart and Lung Research 
animal facilities, respectively.  Experiments were performed with male mice at the ages 
indicated in figure legends.  Given the disparity of genetic background, we used the 
appropriate control animals of indicated genetic background in the experiments. All animal-
based experiments have been approved by the Bioethics Committees of the University of 
Salamanca, CSIC, and Max Planck Institute. 
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In vivo gene recombination 
Unless otherwise stated, this step was done in five-week old male mice using 
intraperitoneal injections of tamoxifen (1 mg/day, Sigma) solubilized in corn oil (Sigma) 
for five consecutive days.  As control, parallel cohorts of mice were injected as above with 
just corn oil.  
 
Determination of mRNA abundance 
RNA was extracted from either mouse organs or primary vSMCs with TRIzol (Sigma) and 
the abundance of indicated transcript determined by qRT-PCR using the ScriptOne-Step 
RT-PCR Kit (Bio-Rad), the StepOnePlus Real-Time PCR System (Applied Biosystems), 
and the StepOne software v2.1 (Applied Biosystems) (22). Expression of the endogenous 
mouse P36b4 transcript was used as normalization control.  Primers used were 5’-CAT 
ACG ACG TCC CAG ACT AC-3’ (forward for mouse Vav2 cDNA), 5’-GGC ATG ACT 
GAG GAC GAC AA-3’ (forward for mouse OncoVav2 cDNA), 5’-
ACATCGATGGCTCGCAGAAA-3’ (reverse for both Vav2 and OncoVav2 cDNAs), 5’-
TAT GGG ACA CAG CTG GAC AA-3’ (forward for mouse Rac1 cDNA), 5’-ACA GTG 
GTG TCG CAC TTC AG-3’ (reverse for mouse Rac1 cDNA), 5’-CCT TCC TGA CAC 
CTC TCT CG-3’ (forward for mouse Rac2 cDNA), 5’-GAG CTC AGA CCC TCA CTT 
GG-3’ (reverse for mouse Rac2 cDNA), 5’-TGC CAT CTC CTT TCA GGT GAT-3’ 
(forward for mouse Cdc42 cDNA), 5’-CGA AAG CTT CAG CCA GTT GTT-3’ (reverse 
for mouse Cdc42 cDNA); 5’-GAA GGA CCT TCG GAA TGA CGA-3’ (forward for 
mouse Rhoa cDNA), 5’-TTC CCA CGT CTA GCT TGC AGA-3’ (reverse for mouse Rhoa 
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cDNA), 5’-TTG ATG ATG GAG TGT GGC ACC-3’ (forward for mouse P36b4 cDNA) 
and 5’-GTG TTT GAC AAC GGC AGC ATT-3’ (reverse for mouse P36b4 cDNA). To 
calculate copy number of Rac1 and Rac2 transcript in vSMCs, two titration curves were 
calculated using serial dilutions of known concentration of plasmids encoding mouse Rac1 
(pNM032) and Rac2 (pNM007) cDNAs (23).  
 
Isolation, culture and stimulation of primary vSMCs 
Aortas were collected from two-month old mice, cleaned to eliminate endothelial cells, 
adipocytes and connective tissue, and finally cut in approximately 5 x 5 mm segments and 
cultured in Dulbecco’s modified Eagle medium (Gibco Life Technologies) supplemented 
with 10% fetal bovine serum, 2 mM L-glutamine and antibiotics (100 units/ml penicillin 
and 100 µg/ml streptomycin, Invitrogen), at 37ºC in a 5% CO2 atmosphere. Culture media 
were changed every 48 hours. After two weeks, aorta pieces were removed and primary 
vSMCs were trypsinized (1x Dissociation Reagent, Gibco Life Technologies), plated onto 
new plates, and maintained in standard culture medium as above. This stage was considered 
passage 1.  To induce the elimination of the Rac1 allele, passage #1 Myh11-Rac1flox/flox cells 
were cultured in the presence of 1 µM 4OHT in ethanol (Sigma).  As control, parallel 
cultures were incubated in the presence of vehicle alone.  After 48 hours, the media was 
replaced by standard culture media.  Experiments were performed using passage 2 cells.  
When required, cells were stimulated with SNP (10 µM, Sigma), AngII (1 µM, Sigma) or 
platelet-derived growth factor (20 ng/ml, Peprotech). In the latter two cases, cells were 
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previously made quiescent by starving them overnight. When indicated, cells were treated 
with Zaprinast (10 µM, Tocris) 30 min before SNP addition to cultures. 
 
Determination of the active fraction of Rho GTPases 
Amount of GTP-bound RhoA and Rac1 in cell lysates was determined using the Rho G-
LISA kit (Cytoskeleton). When indicated, primary vSMCs were challenged with SNP for 
60 min prior to cell lysis.  Plates were read with a Synergy 4 plate reader (BioTek) with 
Gen5 software (BioTek). 
 
Hemodynamic studies 
Systolic, diastolic and mean blood pressures were recorded in conscious mice using a non-
invasive tail cuff method (CODA, Kent Scientific) (18). The same system was used to 
record in real time the heart rates of animals.  To avoid stress-induced changes in those 
physiological parameters, we subjected mice to similar manipulations during the week 
previous to the study in order to familiarize them with the experimental procedure. 
 
Immunoblotting 
Total protein lysates from aortas or primary vSMC cultures were obtained and transferred 
onto nitrocellulose filters as previously described (11, 24).  Filters were blotted with 
antibodies to Rac1 (BD Bioscience; cat. number 610651; dilution, 1:1000), phospho-MLC 
(Rockland; cat. number 600-401-416; dilution, 1:1000), MLC (Cell Signaling; cat. number 
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3672; dilution, 1:1000) or tubulin α (Calbiochem; cat. number CP06; dilution, 1:1000). 
Secondary antibodies were from GE Healthcare. 
 
Histological analyses 
Tissues were fixed in 4% paraformaldehyde in phosphate-buffered saline solution, paraffin-
embedded, cut in 2-3 µm sections, and finally stained with hematoxylin and eosin (Sigma).  
All these procedures were done by independent personnel of the Pathology Unit of our 
center.  Aorta media walls and cardiomyocyte areas were quantified with MetaMorph 
software (Universal Imaging). 
 
Tissue fibrosis determinations 
The content of hydroxyproline in tissue was determined with a spectrophotometric method 
as described (18). We calculated total collagen assuming that collagen contains a 12.7% of 
hydroxyproline. 
 
In vivo drug treatments 
Sildenafil (20 mg/kg body weight/d; Pfizer), L-NAME (700 mg/l, Sigma), captopril (100 
mg/ml, Sigma), propranolol (25 mg/l, Sigma), atropine (4 mg/l, Braun), and doxazosin (30 
mg/l, Pfizer) were added in drinking water for the indicated periods of time. AngII (1.44 
mg/kg/day, Sigma) was administered during 14 days with osmotic pumps (Model 1002, 
Alzet) inserted subcutaneously. When required, AngII and adrenergic receptor inhibitors 
were combined as above. 
Fabbiano et al. (2014) 
	 11	
 
Blood vessel reactivity experiments 
Mesenteric beds from exsanguinated animals were dissected out and quickly placed in ice-
cold Krebs-Henseleit solution (118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM 
KH2PO4, 1.2 mM MgSO4x7H2, 25 mM NaHCO3, 11 mM glucose, pH = 7.4). Both first- 
and second-order mesenteric arteries (≈150 µm in diameter) were dissected, the 
surrounding connective tissue eliminated, and cut into 2 mm rings.  These procedures were 
done under a stereomicroscope.  Two tungsten wires (25 µm diameter) were introduced 
through the vessel lumen and mounted on a four-channel myograph (DMT A/S, Denmark) 
containing 5 ml of Krebs solution at 37 ºC gassed with carbogen. After a 20 min 
equilibration period in Krebs solution, the rings were “normalized” to determine optimal 
active tension development and standardize experimental conditions. At the start of each 
experiment, vessel rings were activated with 120 mM K+ and, subsequently, the response to 
serial concentrations of either phenylephrine (10−8 to 10−4 M) or 5-hydroxytryptamine (10−9 
to 10−5 M) analyzed. Cumulative concentration response curves to acetylcholine (10−8 to 
10−4 M) were also performed upon precontraction with 3 x 10−6 M phenylephrine. To 
compare concentration-response curves, statistical analysis were performed with the 
GraphPad Prism 5.0 software according to the extra sum of squares F test principle. 
 
cGMP production assays 
Basal and sodium nitroprusside-induced amount of cGMP in cultured vSMCs was 
determined an enzyme-linked immunosorbent assay (ELISA) kit (Cyclic GMP EIA Kit; 
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Cayman Chemical) following the supplier’s specifications.   
 
Neointima formation assays 
Left-carotid ligation and sample processing were performed as described before (25). 
Paraffin-embedded samples were stained with orcein (Merck) and neointima formation was 
quantified with ImageJ software. 
 
In vitro migration and proliferation assays 
To measure cell migration, monolayers of primary vSMC in 6-well plates were scratched 
with a pipette tip and maintained under standard culture conditions.  Closure of the wound 
was measured under the microscope (Zeiss) every 12 hours. Wound size was calculated 
with the ImageJ software. Each experiment was performed in triplicate. To facilitate the 
visualization of cells under the microscopy, they were stained with CellTracker Green 5-
chloromethylfluorescein diacetate (10 µg/ml, Invitrogen) prior to the wound healing 
experiment.  To measure cell proliferation, cultures of vSMCs maintained in six-well plates 
were serum-starved overnight and, when appropriate, subsequently stimulated with platelet-
derived growth factor (20 ng/ml, Peprotech). At the indicated periods of time, the medium 
was removed and cells maintained for one hour at 37 ºC in 100 µl of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (0.5 mg/ml in phosphate-buffered 
saline solution, Sigma). Upon removal of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, cells were lysed in Dulbecco’s modified Eagle medium 
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(Sigma) and absorbance read at 570 nm using a spectrophotometer (SmartSpec 3000, 
BioRad). 
 
Analysis of cardiovascular- and blood-related molecules 
We used ELISA-based kits to determine the amount of serotonin (Serotonin ELISA kit, 
IBL), AngII (Angiotensin II ELISA kit; SPI Bio), noradrenaline (CatCombi ELISA; IBL) 
and adrenaline (CatCombi ELISA; IBL) present in the plasma of mice (17, 18, 26).  The 
amount of choline in plasma was determined using the Choline/Acetylcholine Assay Kit 
(Abcam) (26). Plates were read with a Synergy 4 plate reader and analyzed with the Gen5 
software. All experiments were performed following the suppliers’ instructions.  
 
Image processing 
Images were assembled and processed for final figure presentation using Canvas 9.0.4 
(Deneba Systems). 
 
Statistics 
Data were analyzed with either a two-tailed Student’s t test or a one-way ANOVA with 
Bonferroni post hoc test (in the case of multiple comparisons). Sample size was chosen to 
obtain statistically significant conclusions.  In the case of experiments involving tamoxifen-
inducible mice, mice were randomly picked to carry out the injections with vehicle and 
tamoxifen. With the exception of immunohistochemical data, score of experiments was not 
done blindly. No samples were excluded from final analyses.  Results with a P value ≤ 0.05 
Fabbiano et al. (2014) 
	 14	
were considered as statistically significant. 
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RESULTS 
The Vav2 route present in vSMCs contributes to blood pressure regulation in a fully 
autonomous manner 
To assess the direct contribution of vSMC-specific Vav2 signaling to blood pressure 
control, we generated a mouse strain that can express a constitutively active version of 
Vav2 under the regulation of the endogenous Vav2 gene promoter in either an inducible or 
constitutive manner (Fig. 1A). To this end, we used standard genomic recombination 
techniques to insert an ectopic cassette containing a cDNA fragment encoding a truncated, 
HA-tagged Vav2Δ1-184 mutant protein (from now on, OncoVav2) downstream of the first 
exon of the mouse Vav2 locus. We have shown before that this type of truncated Vav 
proteins show phosphorylation-independent, constitutive exchange activity due to the 
removal of the N-terminal inhibitory domains (14, 27-29). To make it possible the 
inducible expression of this protein, this cassette contained 5’-located Stop-NeoR DNA 
sequences flanked by loxP sites (Fig. 1A). Upon generation of mice containing this mutant 
Vav2 locus (Fig. 1A, points 1-2), they were crossed with the already described Myh11-Cre-
ERT2 (21) line to generate the inducible Myh11-Cre-ERT2;Vav2loxP-Stop-NeoR-loxP-HAOncoVav2/loxP-Stop-
NeoR-loxP-HAOncoVav2 mouse strain (designated hereafter as Myh11-OncoVav2) (Fig. 1A, points 3 
and a). Myh11-Cre-ERT2 mice express a fusion protein composed of the Cre recombinase 
and a mutant version of the estrogen receptor domain (Cre-ERT2) under the regulation of 
Myh11 gene promoter, thus allowing the Cre-dependent inactivation of desired target genes 
in vascular, bladder, and intestinal smooth muscle cells when tamoxifen is administered to 
animals (21). Since this transgene is integrated in the Y chromosome, the recombination 
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step is limited to males (21). Due to the experimental strategy chosen, mice homozygotes 
for the mutant loxP-Stop-NeoR-loxP-HAOncoVav2 allele will lack expression of 
endogenous wild type Vav2 and, therefore, are expected to behave as standard Vav2–/– 
knockout mice (Fig. 1, A and B). Upon the tamoxifen-mediated activation of the Cre-ERT2 
chimera, OncoVav2 will be specifically expressed in SMCs due to the removal of the 
upstream Stop-NeoR sequences (Fig. 1A, point 4; Fig. 1B). However, the rest of tissues of 
these mice will remain Vav2-deficient due to the lack of expression of the Cre-ERT2 fusion 
protein in them (Fig. 1B). Consistent with the planned strategy, we demonstrated using 
qRT-PCR that aortas from Myh11-OncoVav2 mice lack wild type Vav2 transcripts and can 
express the OncoVav2 mRNA in a tamoxifen-dependent manner (Fig. 1C). As a second 
experimental model, we generated a mouse line (designated from now on as C-OncoVav2) 
engineered to express OncoVav2 in all tissues and age periods where the Vav2 gene is 
transcriptionally active (Fig. 1A, points 5 and b). Using GTPase-linked immunosorbent 
assays, we found that the expression of OncoVav2 under those conditions leads to an 
increase in the basal levels of GTP-bound Rac1 (1.5 ± 0.2 versus control, P ≤ 0.05, n = 3) 
and RhoA (1.4 ± 0.1 versus control, P ≤ 0.05, n = 3) in cultured vSMCs. This dual strategy 
allowed us to assess the specific contribution of both SMC-specific and ubiquitous Vav2-
activated signaling routes to the regulation of vascular tone in vivo. In addition, it made it 
possible to investigate whether the inducible expression of OncoVav2 in vSMCs could 
counteract the hypertensive effects derived from the systemic loss of wild type Vav2 (11, 
17). 
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 Consistent with the lack of wild type Vav2 (11, 17), we observed that the non-
induced Myh11-OncoVav2 mice develop hypertension (Fig. 1D, red line; Fig. 1E, red 
bars) and tachycardia (Fig. 1F, red bars) in an age-dependent manner. However, when the 
expression of OncoVav2 is induced in vSMCs before the development of the hypertensive 
state in these animals (Fig. 1D, point a), it progressively promotes a hypotensive state (Fig. 
1D, thick blue line; Fig. 1E, blue bars). Such phenotype is maintained even at ages when 
the non-induced Myh11-OncoVav2 mice typically develop a hypertensive state (Fig. 1D, 
compare red and thick blue lines) (11, 17). Most notably, the tamoxifen-induced expression 
of OncoVav2 in vSMCs of mice with full-blown hypertension (Fig. 1D, point b) results in 
the rapid drop of arterial blood pressure and the acquisition of a hypotensive state (Fig. 1D, 
compare red and thin blue lines; Fig. 1E, blue bars). The specific expression of OncoVav2 
in SMCs also eliminates the tachycardia exhibited by these mice, leading to heart rates 
comparable to those found in controls (Fig. 1F, blue bars). All the above alterations are 
OncoVav2-dependent, because tamoxifen does not trigger them when injected in either 
female Myh11-OncoVav2 mice (which do not carry the transgene) or in male Myh11-Cre-
ERT2 mice lacking the OncoVav2 allele (SF and XRB, data not shown). The analysis of C-
OncoVav2 mice (Fig. 1, A and G) revealed the presence of a constitutive hypotensive state 
from very early post-natal ages (Fig. 1, H and I). Such phenotype is maintained even in 
mice heterozygote for the OncoVav2 and null Vav2 alleles (Fig. 1I), indicating that it can 
be triggered even with 50% of the normal amount of OncoVav2 protein expressed. The 
basal heart rate exhibited by C-OncoVav2 mice, however, does not significantly change 
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when compared to controls (Fig. 1J). Taken together, these results indicate that mice only 
require the Vav2 route present in vSMCs to ensure full arterial blood pressure control. 
Vav2 and Rac1 are commonly involved in blood pressure regulation 
Vav2 can activate a number of Rho subfamily GTPases, including Rac1, RhoG, RhoA and, 
in reports from some groups, Cdc42 (15). We demonstrated before that Rhog–/– mice do not 
develop hypertension (17), ruling out the implication of RhoG in Vav2-dependent roles in 
vascular tone regulation. It is also unlikely that such function is mediated by RhoA, giving 
the well-known implication of this GTPase in vasoconstriction-related vSMC responses (1). 
To investigate the implication of the remaining GTPases in this signaling route, we 
generated new mouse strains that allowed the specific, chemically inducible depletion of 
either Rac1 or Cdc42 in SMCs.  To this end, we first crossed the Myh11-Cre-ERT2 with the 
previously described Rac1flox/flox (30) line to establish the compound Myh11-Cre-
ERT2;Rac1flox/flox (referred from now on as Myh11-Rac1flox/flox). Using quantitative RT-PCR 
analysis, we demonstrated that the injection of tamoxifen in these mice promotes the 
expected reduction of Rac1 transcripts in the aortas of the appropriate strains (Fig. 2A). 
This effect is specific, since the abundance of transcripts for Rac2, Cdc42 and RhoA does 
not change in a statistically significant manner under those conditions (Fig. 2A). The 
addition of 4OHT to in vitro cultures of primary vSMCs from male Myh11-Rac1flox/flox mice 
also results in a rapid, five-fold reduction in the total abundance of the Rac1 transcripts 
(Fig. 2B, left panel). In this case, however, we observed a concomitant, four-fold increase 
in the number of Rac2 mRNA copies present in those cells at late 4OHT administration 
periods (Fig. 2B, right panel). Despite such upregulation, the number of copies of this 
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transcript per ng of total RNA under those conditions is still ≈60 fold lower than those for 
the Rac1 mRNA in control cells (Fig. 2B). Note that the smaller fold-change in the 
abundance of the Rac1 mRNA in aortas than in cultured vSMCs is probably due to the 
remaining expression of the Rac1 gene in endothelial and other cells present in vessels.  
Using Western blot analyses, we could also demonstrate a marked depletion of the 
endogenous Rac1 protein in aortas upon the addition of tamoxifen to Myh11-Rac1flox/flox 
mice (Fig. 2C, upper panel). Using this mouse model, we found that the inactivation of the 
Rac1 gene promotes the development of high mean (Fig. 2D), systolic (Fig. 2E), and 
diastolic (Fig. 2F) arterial pressures in Myh11-Rac1flox/flox mice. This hypertension develops 
quite rapidly upon the tamoxifen administration and remains rather stable throughout the 
rest of the time course analyzed (Fig. 2D). We also observed parallel changes in other 
cardiovascular parameters, including increased amounts of MLC phosphorylation in aortas 
(Fig. 2C, second panel from top), tachycardia (Fig. 2G), cardiovascular remodeling (Fig. 2, 
H to J), and development of fibrosis in both heart and kidneys (Fig. 2K). Cdc42 does not 
seem to be involved in this process, because the analysis of tamoxifen-treated Myh11-Cre-
ERT2;Cdc42flox/flox mice revealed that the vSMCs-specific depletion of this GTPase (Fig. 2L) 
does not have any significant impact on basal blood pressure in mice (Fig. 2M). Taken 
together, these results indicate that the Vav2-Rac1 signaling axis present in vSMCs has a 
direct role in the regulation of arterial blood pressure that, depending on how the signal 
output of the pathway is modified, can lead to either hypotension (when upregulated) or 
hypertension (when downregulated). 
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The Vav2-Rac1 pathway is important for acetylcholine-dependent vasodilation 
responses in vSMCs 
To analyze the reactivity of blood vessels in our mouse lines, we investigated the effect of 
both vasopressor and vasodilation molecules on mesenteric artery rings ex vivo. We found 
that vessels from tamoxifen-treated Myh11-OncoVav2 have slightly increased pressor 
responses to high concentrations of vasoconstrictor agents such as phenylephrine (Fig. 3A) 
and 5-hydroxytryptamine (Fig. 3B). This seems to be a specific feature of OncoVav2-
expressing vessels, because the lack of wild type Vav2 in both standard Vav2–/– (11) and oil-
treated Myh11-OncoVav2 (Fig. 3, A and B) does not induce any negative effect in those 
responses. The physiological impact of this enhanced contractility response does not seem 
very relevant in vivo, since OncoVav2-expressing mice display basal hypotension rather 
than hypertension (see above, Fig. 1, D and E). We surmise that this reactivity may derive 
from the OncoVav2-mediated activation of RhoA detected in vSMCs (see above) or, 
alternatively, a hypotension-associated compensatory mechanism that could have 
developed in tamoxifen-treated mice. As expected (11), the phenylephrine-precontracted 
mesenteric arteries from oil-injected Myh11-OncoVav2 mice do show poor relaxation 
responses to acetylcholine due to the lack of Vav2 expression (Fig. 3C). This molecule 
triggers NO production in vascular endothelial cells and, subsequently, the NO-dependent 
stimulation of the soluble guanylate cyclase-cGMP-protein kinase G1 axis that results in 
the abrogation of RhoA-dependent actomyosin contractility in vSMCs (31).  Such 
physiological response is restored, although not exacerbated, when OncoVav2 is expressed 
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in those mice (Fig. 3C). Using the same strategy, we observed that mesenteric arteries from 
control and tamoxifen-treated Myh11-Rac1flox/flox mice exhibit similar pressor responses to 
phenylephrine (Fig. 3D), 5-hydroxytryptamine (Fig. 3E), thromboxane (Fig. 3F), 
endothelin-1 (Fig. 3G) or AngII (Fig. 3H). By contrast, and similarly to results found in 
aortas from Vav2–/– knockout mice (11), we observed that phenylephrine-precontracted 
mesenteric arteries from tamoxifen-treated Myh11-Rac1flox/flox mice do undergo defective 
relaxation responses to acetylcholine when compared to those from control mice (Fig. 3I). 
These results indicate that the Vav2-Rac1 signaling axis present in vSMCs plays central 
roles in NO-mediated vasodilation responses in mesenteric arteries. By contrast, it seems to 
be totally dispensable for contractile responses triggered by a large variety of vasopressor 
agents.  In addition, they indicate that the vasodilatation defects previously detected in 
Vav2–/– mice can be attributed to specific signal dysfunctions in vSMCs. 
 
The Vav2-Rac1 pathway is important for the NO-mediated inactivation of RhoA 
dependent contractility  
We have previously shown that the vasodilation defects present in arteries of conventional 
Vav2–/– knockout mice seemed to stem from improper phosphodiesterase type 5 inactivation 
during early responses of vSMCs to NO (for a scheme, see Fig. 4A, pathway highlighted in 
light blue color) (11). As a consequence, these cells cannot block the RhoA-Rock2-MLC 
pathway due to the rapid degradation of the cGMP second messenger by phosphodiesterase 
type 5 (Fig. 4A) (11). To investigate whether this defect is also present in Rac1-depleted 
vSMCs, we treated cultures of primary vSMCs from Myh11-Rac1flox/flox mice with 4OHT to 
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induce the Rac1 depletion (see above, Fig. 2B) and, subsequently, evaluated their response 
to the stimulation with a NO donor (sodium nitroprusside, SNP) (32). As control, we 
utilized cultures of Myh11-Rac1flox/flox vSMCs treated with the vehicle (ethanol) used to 
prepare the 4OHT solution. After an extra cell passage, we stimulated cells with SNP and 
measured production of cGMP using an enzyme-linked immunosorbent-based method. 
Similarly to previous results with Vav2–/– vSMCs (11), we observed that the depletion of 
Rac1 severely compromises the production of cGMP in SNP-stimulated vSMCs (Fig. 4B). 
Such defect is eliminated when vSMCs are pre-treated before the SNP stimulation step with 
Zaprinast (Fig. 4B), a phosphodiesterase type 5 inhibitor (33). Consistent with these results, 
we found using both GTPase-linked immunosorbent and Western blot assays that Rac1-
depleted vSMCs cannot trigger the expected reduction in the amount of active RhoA (Fig. 
4C) and phospho-MLC (Fig. 4D) that take place during SNP stimulation conditions. 
Similar defects were seen in SNP-stimulated vSMCs from Vav2–/– knockout mice (Fig. 4D) 
(11). These results indicate that the single depletion of either Vav2 or Rac1 proteins 
triggers similar NO-dependent signaling defects in vSCMs. Given these results, we 
speculated that the expression of OncoVav2 in vSMCs could favor a stronger inhibition of 
phosphodiesterase type 5 under NO stimulation conditions. To test this possibility, we 
compared both the basal and SNP-induced concentration of cGMP in vSMCs obtained 
from control and C-OncoVav2 mice. Despite displaying control-like concentrations of 
cGMP under non-stimulated conditions, we did find that SNP-stimulated OncoVav2-
expressing vSMCs promote higher and more sustained amounts of cGMP than control cells 
(Fig. 4E). However, the expression of OncoVav2 does not seem to achieve full inhibition 
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of phosphodiesterase type 5 catalytic activity, because the amount of cGMP generated by 
C-OncoVav2 vSMCs can be further increased when Zaprinast is included in these 
experiments (Fig. 4E). 
 To corroborate the above results in vivo, we evaluated the effect of the 
phosphodiesterase type 5 inhibitor sildenafil on the hypertension of tamoxifen-treated 
Myh11-Rac1flox/flox. As positive control, we carried out parallel experiments with standard 
Vav2–/– mice. We have shown before that the hypertension of these mice could be 
eliminated by the long-term administration of that drug (11). As negative control, we 
utilized standard Vav3–/– knockout mice. The hypertension of these latter animals is 
sympathetic-based (18, 34) and, therefore, cannot be eliminated by the in vivo 
administration of PDE inhibitors (11). We found that the oral administration of sildenafil 
for just one week readily eliminates the hypertension of both tamoxifen-treated Myh11-
Rac1flox/flox (Fig. 4F) and standard Vav2–/– knockout (Fig. 4G) mice. Such effect is specific, 
because sildenafil does not affect the basal blood pressure of both oil-treated Myh11-
Rac1flox/flox (Fig. 4F) and Vav2+/+ (Fig. 4G) mice. Likewise, it cannot cure the hypertension 
exhibited by Vav3–/– mice (Fig. 4G). Also consistent with the implication of this route in 
NO signaling, we observed that the in vivo administration of Nω-Nitro-L-arginine methyl 
ester (L-NAME), a NO synthase catalytic inhibitor that promotes hypertension through the 
inhibition of vSMC-dependent vasodilatation, promotes the elevation of the basal blood 
pressure of control mice whereas it does not have any significant effect on the already 
hypertense tamoxifen-treated Myh11-Rac1flox/flox mice (Fig. 4H). By contrast, L-NAME-
treated C-OncoVav2 mice do show a hypertensive response (Fig. 4I), indicating that the 
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hyperactivation of the Vav2-Rac1 pathway does not confer any benefit under conditions of 
optimal ablation of nitric oxide signaling. These responses are L-NAME-specific, because 
tamoxifen-treated Myh11-Rac1flox/flox mice do show enhanced pressor responses when 
systemically infused with AngII when compared to controls (Fig. 4J). Conversely, C-
OncoVav2 animals undergo milder pressor responses than control mice under these 
experimental conditions (Fig. 4K). Taken collectively, these findings confirm that the 
Vav2-Rac1 route is fully signaling autonomous to promote the inactivation of 
phosphodiesterase type 5 and effective nitric-oxide vasodilation responses in vSMCs. 
 
Rac1, but not Vav2, contributes to specific vascular remodeling events 
We next investigated whether the Vav2-Rac1 signaling pathway present in vSMCs could 
be implicated in specific vascular-related pathologies.  In contrast to previous inferences 
(1), we excluded the implication of Rac1 in hypertension-driven vascular remodeling, 
because the tamoxifen-treated Myh11-Rac1flox/flox mice showed no marked alterations in the 
thickening of arterial media walls typically seen under most systemic hypertension 
conditions (see above, Fig. 2H) (1, 35). Vav2 is not involved either, because Vav2–/– (11, 
17) and non-induced Myh11-OncoVav2 (S.F. and X.R.B., data not shown) mice also show 
normal vascular remodeling upon developing hypertension. Similar results were found in 
Vav3–/– and Vav2–/–;Vav3–/– mice (17, 18), ruling out that members of this family are in 
charge of this pathological process. To investigate the possible implication of these proteins 
in other vascular remodeling processes, we next performed neointima formation assays in 
both Myh11-Rac1flox/flox and standard Vav2–/– mice. To this end, we ligated one of the 
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carotid arteries of these mice and, subsequently, measured the neointima formed in both 
proximal and distal histological cross sections of the ligated carotids. As control, we 
analyzed similar sections from nonligated carotids. We found defective neointima 
formation in tamoxifen-treated Myh11-Rac1flox/flox (Fig. 5, A and B) but not in Vav2–/– 
animals (Fig. 5, C and D). Consistent with this, we observed using both wound healing and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide incorporation assays that the 
4OHT-induced depletion of Rac1 significantly reduced both the migration (Fig. 5, E and F) 
and platelet-derived growth factor-induced proliferation (Fig. 5G) of primary vSMCs. 
Vav2–/– vSMCs behave exactly as their control counterparts in these two assays (Fig. 5, E to 
G). However, the migration of vSMCs is Vav-family dependent, because single Vav3–/– and 
compound Vav2–/–;Vav3–/– vSMCs show ineffective wound healing activity when compared 
to controls (Fig. 5F). By contrast, the proliferation of vSMCs seems to be fully Vav-
independent (Fig. 5G). Taken together, these results indicate that the Rac1 route in vSMCs 
is important for both vascular tone regulation and neointima formation (Fig. 5H). In 
addition, they show that the activation of this GTPase in vSMCs requires the participation 
of different subsets of upstream exchange factors depending on the signaling route and 
biological process involved (Fig. 5H). 
 
Rac1 signaling dysfunctions in vSMCs promote activation of systemic, 
prohypertensive pathophysiological programs in mice 
In addition to the regulation of vascular tone, the development of a hypertensive state 
requires changes in renal and heart activities (1). Up to now, however, it was rather difficult 
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to establish the evolution in time of these physiological circuits upon a local dysfunction in 
vascular tone and to figure out how they are hierarchically organized during such process. 
The availability of the tamoxifen inducible Myh11-Rac1flox/flox mice offered us the 
opportunity to address this issue in a rather genetically- and physiological-clean manner 
because, in this case, the depletion of this protein is circumscribed exclusively to SMCs. 
Perhaps more importantly, we believed that the use of this experimental model could also 
contribute to unveil potential synergisms between these vSMC extrinsic and intrinsic 
prohypertensive mechanisms that could favor the development and/or maintenance of the 
hypertensive state. To address those issues, we decided to monitor the evolution of blood 
pressure, heart activity, AngII, serotonin, catecholamines, and choline (an indirect read-out 
for parasympathetic activity) upon the vSMC-specific Rac1 depletion in Myh11-Rac1flox/flox 
mice. Given that some clinical data have linked peripheral vasoconstriction with 
development of type 2 diabetes (36, 37), we also included the evaluation of this parameter 
in our study. We found using that strategy that the first alteration observed in these mice is 
the elevation of blood pressure, since it is detected and reaches a plateau just one week 
upon the termination of the tamoxifen treatments (Fig. 2E). Other alterations that take place 
rapidly upon the tamoxifen treatment include the reduction in plasma levels of both choline 
(Fig. 6A) and serotonin (Fig. 6B). These changes are only transient in the case of serotonin 
(Fig. 6, A and B). Although a known vasoconstrictor, plasma serotonin levels are usually 
downregulated in hypertensive conditions due to functional changes in platelets, the main 
reservoir of this substance in the blood (38). The elevation of AngII in plasma becomes 
statistically significant two weeks upon the Rac1 depletion, reaching maximal amounts at 
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the fourth post-treatment week (Fig. 6C). By contrast, the plasma concentrations of both 
noradrenaline (Fig. 6D) and adrenaline (Fig. 6E) only become statistically significant four 
weeks after the tamoxifen injections. The tachycardia found in these animals (see above, 
Fig. 2G) develops and reaches maximal levels a week later than the hypertensive response 
(Fig. 6F). The increase in heart rate activity is probably initiated by the drop in 
parasympathetic activity, since it coincides with the time of reduction in the amount of 
choline in the plasma of these animals (Fig. 6A). Furthermore, it takes place several weeks 
before the upregulation of catecholamines in the system (Fig. 6, D and E). By contrast, we 
could not detect any abnormal insulin-dependent response (Fig. 6G) or signs of metabolic 
syndrome in the liver (Fig. 6, H and I), white adipose tissue (Fig. 6H), and brown adipose 
tissue (Fig. 6H) in these animals. A summary of all these pathophysiological changes is 
included in Figure 7A. 
 
vSMC signaling dysfunctions require cross-talk with systemic vasopressor 
mechanisms to both induce and maintain hypertensive states 
To investigate whether the pathophysiological changes observed in these mice were 
required to sustain the hypertensive phenotype of tamoxifen-treated Myh11-Rac1flox/flox 
mice, we next evaluated the effect that the serial administration of AngII biosynthesis 
(captopril) and nonselective β-adrenergic receptor (propranolol) inhibitors induced in the 
hypertension of these mice. Similarly to the administration of sildenafil (Figs. 4F and 7B), 
we found that the transient treatment of these animals with captopril and propranolol results 
in the rapid elimination of the hypertensive state (Fig. 7, A and B). This effect is abrogated 
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when each of these drugs is removed (Fig. 7B). These three inhibitors exert the same 
antihypertensive effect when independently administered to tamoxifen-treated Myh11-
Rac1flox/flox mice (Fig. 7C, left panel). Interestingly, we found that they also block the initial 
surge in blood pressure when administered both prior to and shortly after the gene 
recombination event (Fig. 7C, right panel). This suggests that the activation of the renin-
AngII and sympathetic systems starts well before their systemic elevation in plasma. Local 
effects of RAS in kidneys without concomitant elevations in plasma AngII levels have been 
previously found in L-NAME-triggered hypertension (39, 40). Importantly, this 
pathophysiological cadre seems to be fully dependent on the primary signaling dysfunction 
in vSMCs, as assessed by the rapid elimination of both the hypertension and tachycardia of 
Myh11-OncoVav2 mice upon the specific expression of OncoVav2 in vSMCs (see above, 
Fig. 1, D to F). Taken together, these findings indicate that the development and 
maintenance of the hypertension of Rac1-depleted mice requires the reciprocal cooperation 
of the intrinsic vSMC signaling defects and the extrinsic pathophysiological programs 
activated by them. 
 
The renin-AngII system is key in the consolidation of the hypertensive phenotype 
induced by the Rac1 depletion in vSMCs 
The above data indicated that the initial change in vascular tone derived from defective 
Rac1 signaling in vSMC requires the engagement of additional downstream physiological 
responses to generate a fully blown and stable hypertensive condition. Moreover, they 
suggested that this pathophysiological cadre evolves in a hierarchical manner, since the 
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changes in the renin-AngII and parasympathetic systems are detected much earlier than 
those linked to the SNS. The stimulation of the RAS is probably one of the most important 
changes for the development of the hypertensive state of Myh11-Rac1flox/flox mice because, 
in addition to the elimination of the hypertensive state (see above, Fig. 7, A to C), the in 
vivo administration of captopril eliminates the deregulated levels of heart activity, plasma 
choline and plasma catecholamines present in tamoxifen-treated Myh11-Rac1flox/flox mice 
(Table I and Fig. 7A, see “Capt” column). Consistent with this, we observed that the 
systemic administration of AngII to wild type mice phenocopies the cardiovascular-related 
pathophysiological dysfunctions seen in tamoxifen-treated Myh11-Rac1flox/flox mice (Table I 
and Fig. 7A, see “AngII” column inside box shaded in gray). The cardiovascular-related 
effects elicited by AngII are seen even when coadministered with both α- (doxazosin) and 
β- (propranolol) adrenergic receptor inhibitors (Table I and Fig. 7A, see “AngII+ARI” 
colum in box shaded in gray), indicating that they are probably caused by direct 
vasopressor effects of AngII rather than by indirect effects on sympathoregulatory brain 
center. Unlike the case of AngII, we found that the systemic administration of competitive 
inhibitor of parasympathetic-stimulated muscarinic acetylcholine receptors (atropine) 
recapitulates some (hypertension, tachycardia), but not all (increases in both AngII and 
noradrenaline) the alterations previously seen in both tamoxifen-treated Myh11-Rac1flox/flox 
and AngII-treated C57BL/10 mice (Table I and Fig. 7A, see “Atr” column in box shaded 
in gray). 
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DISCUSSION 
Here, we have used a number of inducible and constitutive loss- and gain-of-function 
mouse models to address the intrinsic signaling roles of Vav family members and Rac1 in 
vSMCs. Our results indicate that Vav2 and Rac1, but not Cdc42 or RhoG (11), are involved 
in a linear pathway that controls, in a fully cell and signaling autonomous manner, NO- and 
phosphodiesterase type 5-dependent vasodilation responses in these cells. Unlike previous 
results (8-10), we have observed no vessel contractility defects to a large number of 
vasopressor substances in Rac1-depleted mesenteric arteries, indicating that this GTPase is 
not highly relevant for either the engagement or facilitation of vSMC contractility. It is 
possible that the discrepancy with some of those previous results could reflect 
nonphysiological effects of Rac1 inhibitors and ectopically expressed Rac1 mutants used in 
those studies or, alternatively, that such vasoconstriction roles could be circumscribed to 
pathological settings unrelated to normal arterial blood pressure control. The implication of 
the Vav2-Rac1 pathway in NO-dependent vSMC responses is quite interesting from a 
physiological point of view, because Rac1 is known to promote NO biosynthesis in 
endothelial cells (41-43). This suggests that Rac1 has been probably chosen during 
evolution as a common signaling hub to ensure the orchestration of fully coherent and 
optimal relaxation responses along all the NO stimulation cycle of blood vessels. Whether 
Vav2 also plays roles in the regulation of NO production in endothelial cells remains to be 
determined. Our studies have also revealed that the Rac1 pathway is important for some, 
but not all, the functions of vSMCs in vascular remodeling events. Consistent with this, we 
have seen that the thickening of the arterial media walls typically observed during 
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hypertensive states develops normally in both Vav2- and Rac1-deficient mice. By contrast, 
we have found that Rac1 does play critical roles in neointima formation (Fig. 5H). This 
response is Vav2-independent, suggesting the implication of other exchange factors in this 
Rac1-dependent route (Fig. 5H). Possible candidates include ArhGEF7 and Kalirin, since 
these exchange factors promote the proliferation and migration of vSMC in vitro and, in the 
case of Kalirin, neointima formation in vivo (44, 45). Our results suggest that Vav3 can 
also represent a good candidate for this regulatory step (Fig. 5H). Unfortunately, we could 
not verify this possibility because all Vav3–/– mice used in neointima experiments died 
shortly after the ligation step of the carotid (MAS, SF, MJM and XRB, unpublished data). 
The cause for this mortality is unknown, although it may be due to the chronic 
sympathoexcitation present in these mice (18, 34).   
 The inducible nature of some of the mouse models used in this study has also 
allowed us to recapitulate, in a genetically and physiological “clean” manner, the alterations 
that take place at the organism level upon a single vascular tone-related signaling defect in 
vSMCs. We have observed that such alterations include, among others, the progressive 
stimulation of both the RAS and SNS (Fig. 7A). The combined activation of these two 
systems probably favors the evasion of the renal pressure-natriuresis mechanism that 
ensures the long-term arterial pressure homeostasis and, subsequently, the aggravation of 
the hypertensive state through the cardiac-, vasopressor- and vascular remodeling-mediated 
increase in peripheral arterial resistance (46). These two systems become activated very 
early on upon the Rac1 deletion, because captopril and propranolol can halt the 
development of hypertension even when administered prior to the gene recombination 
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event and during short postrecombination periods in which AngII and catecholamines have 
not yet reached systemic levels in plasma. We have also found a very early reduction of 
parasympathetic activity that contributes to the early tachycardic response seen right after 
the Rac1 depletion in vSMCs and, in addition, to the increased vasoconstriction present in 
these mice (Fig. 7A). This latter response is probably a physiological adaptation to elevated 
blood pressure conditions, since it has been also observed both in the neurogenic 
hypertension conditions exhibited by Vav3–/– mice (26) and during the systemic 
administration of AngII to wild type mice (Table I). Taken together, our results indicate 
that the local dysfunction of Vav2 and Rac1 signaling in vSMCs elicits a “butterfly effect” 
that eventually leads to the generation of general prohypertensive pathophysiological status 
in animals. By contrast, we observed that mice depleted of Rac1 in vSMCs do not develop 
type 2 diabetes even after long periods of chronic hypertension and high AngII levels in 
plasma. This is intriguing, because multiple clinical studies have shown associations 
between the development of this disease and the presence of either chronic vasoconstriction 
or systemic AngII conditions (36, 37). It has been argued that such linkage could be due to 
direct effects of the above cardiovascular parameters on insulin responses. Proposed models 
include negative effects induced by vasoconstriction itself in the availability of both 
glucose and insulin in peripheral tissues, intrinsic signaling effects of AngII in pancreatic 
cells, and negative influences of AngII-stimulated pathways on insulin receptor 
downstream signaling elements in a number of cell types (36, 37). However, other studies 
favor the concept that such association reflects an ancillary function of those cardiovascular 
parameters in individuals that are already predisposed to develop type 2 diabetes (37). 
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Answering this issue has been difficult so far in humans given the multiple gender, ethnic, 
metabolic, and lifestyle variables involved in the development of all these diseases. Our 
results tilt the balance in favor of the latter model, since they suggest that chronic 
hypertension and high AngII conditions are not sufficient per se to trigger glucose tolerance 
or type 2 diabetes in the absence of such genetic predisposition, at least in the case of mice. 
 The present results also suggest that the pharmacological inhibition of Rac1 will 
lead to the inexorable development of hypertension and its typical comorbodities. This 
observation is particularly important given the intensive efforts that are currently being 
made to isolate specific inhibitors for exchange factors, exchange factor-Rac1 interactions, 
and the catalytic activity of p21 activated kinase family members to treat cancer patients 
(47, 48). However, our results also indicate that these side effects will be readily eliminated 
upon removal of those therapies or, perhaps more importantly, fully prevented when using 
them in combination with standard anti-hypertension treatments already utilized in clinical 
practice. 
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TABLE I. Effect of indicated treatments in Myh-Rac1flox/flox and wild type C57BL/10 mice. * P ≤ 0.05 when compared with 
the appropriate untreated control; #, P ≤ 0.05 when compared to tamoxifen-treated mice; †, P ≤ 0.05 when compared to AngII-
treated mice.  
 
MOUSE STRAIN 
Myh11-Rac1flox/flox C57BL/10 
+Oila +Tamoxifen 
+Tamoxifen
+ 
Captopril 
Control +AngII +AngII+Prop+Doxab +Atropine 
M.A.P.  
(mmHg) 74 ± 2 87 ±  3
* 72 ±  2# 78 ± 4 112 ±  3* 116 ±  4* 97±2* 
Heart rate  
(b.p.m.) 603 ± 12 709 ±  18
* 570 ±  9# 594 ± 11 697 ±  38* 712 ±  24* 722±15* 
AngII  
(pg/ml) 30 ± 1 97 ±  5
* N.D. 32 ± 3 N.D. N.D. 39±5 
Choline 
(nmol/ul) 0.032 ± 0.01 0.026 ±  0.00
* 0.036 ±  0.00# 0.034 ± 0.00 0.024 ±  0.00* 0.023 ±  0.00* 0.028±0.01 
Noradrenaline 
(nM) 0.88 ± 0.12 1.48 ±  0.14
* 0.66 ±  0.05# 0.62 ± 0.12 1.72 ±  0.22* 1.54 ±  0.3* 0.67±0.12 
 
aSee Materials and Methods for details about treatments performed. 
bProp, propranolol ; Doxa, doxazosine; N.D., not determined. 
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FIGURE 2. Deletion of Rac1 in vSMC leads to hypertension and loss of 
cardiovascular homeostasis. (A) Abundance of indicated transcripts in aortas obtained 
from Myh11-Rac1flox/flox mice three weeks after being subjected to injections with either 
corn oil (Oil) or tamoxifen (TAM). Values obtained for each transcript in control mice were 
given an arbitrary value of 1.  ***, P ≤ 0.001 relative to the appropriate control (n = 5). (B) 
Changes in the number copies of Rac1 (left panel) and Rac2 (right panel) mRNAs in 
4OHT-treated primary vSMCs maintained in cell culture.  (C) Abundance of indicated 
proteins and phospho-proteins (arrows) in total tissue extracts from aortas obtained from 
Myh11-Rac1flox/flox mice that were treated as in A.  Data obtained in two independent 
experiments are shown.  Abundance of tubulin α was used as loading control (bottom 
panels). p, phosphorylated. (D) Evolution of the mean arterial pressure of Myh11-
Rac1flox/flox mice before (shaded area, negative numbers) and after (non-shaded area, 
positive numbers) five consecutive injections (indicated by arrows) of either oil or 
tamoxifen.  The 0 time point indicates the final injection time. *, P ≤ 0.05; ***P ≤ 0.001 
relative to oil-injected mice (n = 6). (E and F) Systolic (S.A.P.; E) and diastolic (D.A.P.; F) 
arterial pressure in Myh11-Rac1flox/flox mice three weeks after the indicated treatments. **, P 
≤ 0.01 relative to control mice (n = 4). (G) Heart rate of Myh11-Rac1flox/flox mice three 
weeks after the indicated treatments. *P ≤ 0.05 relative to oil-injected mice (n = 6).  (H and 
I) Mean aorta media wall size (H) and cell area of left ventricle cardiomyocytes (I) present 
in Myh11-Rac1flox/flox mice three weeks upon final oil and tamoxifen injections. **P ≤ 0.01 
relative to oil-injected mice (n = 6). (J) Representative examples of hematoxylin-eosin-
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stained sections obtained from the indicated tissues of Myh11-Rac1flox/flox mice in the 
experiment indicated in panels G and H.  Scale bars, 100 µm.  (K) Amount of fibrosis in 
indicated tissues from Myh11-Rac1flox/flox mice three weeks upon final oil and tamoxifen 
injections. **P ≤ 0.01 relative to oil-injected mice (n = 4).  In panels B, E to H and J, error 
bars represent the S.E.M. (L) Abundance of indicated transcripts in aortas obtained from 
Myh11-Cdc42floxflox mice three weeks after being subjected to injections with either oil or 
tamoxifen. Values obtained for each transcript in control mice were given an arbitrary value 
of 1. ***, P ≤ 0.001 relative to the appropriate control (n = 4). (M) Comparison of the 
mean arterial pressure of oil- and tamoxifen-treated Myh11-Cdc42floxflox mice. **, P ≤ 0.01 
relative to control mice (n = 8). Error bars in graphs of this figure represent the S.E.M. The 
difference in basal blood pressure between control Myh11-Cdc42floxflox and Myh11-
Rac1flox/flox mice is probably due to their different genetic background. 
 
FIGURE 3. The Vav2-Rac1 axis of vSMCs is important for acetylcholine-dependent 
vasodilation responses. (A and B) Contractile response to indicated concentrations of 
phenylephrine (A) and 5-hydroxytryptamine (B) of mesenteric arteries isolated from 2-
month old Myh11-OncoVav2 mice subjected three weeks before to injections with either 
oil or tamoxifen. *, P ≤ 0.001 of the fit parameters concentration-response curves compared 
to those control mesenteric arteries (n = 4 and 6 for oil- and tamoxifen-treated mice, 
respectively). (C) Relaxation response to indicated concentrations of acetylcholine of 
mesenteric arteries isolated as indicated in A and B. *, P ≤ 0.001 of the fit parameters 
concentration-response curves compared to those control mesenteric arteries (n = 4 and 6 
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for oil- and tamoxifen-treated mice, respectively). (D to G) Contractile response to 
indicated concentrations of phenylephrine (D), 5-hydroxytryptamine (E), a thromboxane A2 
receptor agonist (U46619) (F) and endothelin-1 (G) of mesenteric arteries isolated from 
two-month old Myh11-Rac1flox/flox mice that were subjected three weeks before to injections 
with either oil or tamoxifen.  n = 5 and 9 for oil- and tamoxifen-treated mice, respectively). 
(H) Ex vivo contractile response of mesenteric arteries from oil- and tamoxifen-injected 
Myh11-Rac1flox/flox mice to a single dose of AngII (1 x 10-7). n = 5 and 11 for oil- and 
tamoxifen-treated mice, respectively. (I) Relaxation response to indicated concentrations of 
acetylcholine of mesenteric arteries from two-month old Myh11-Rac1flox/flox mice that were 
subjected three weeks before to injections with either oil or tamoxifen. ***, P ≤ 0.001 of 
the fit parameters concentration-response curves compared to those control mesenteric 
arteries (n = 5 and 9 for oil-treated tamoxifen-treated mice, respectively). Error bars in 
graphs of this figure represent the S.E.M. 
 
FIGURE 4. The Vav2-Rac1 route is critical for the NO-mediated inhibition of RhoA-
dependent contractile routes in vSMCs. (A) Scheme of signaling routes present of vSMC 
involved in vasoconstriction (red colors) and vasodilatation (blue colors) responses. GPCR, 
G-protein coupled receptor; PLCβ, phospholipase β; MLCK, MLC kinase; GEF, GDP/GTP 
exchane factor; MLCP, MLC phosphatase; sGC, soluble guanylate cyclase; PrkG1, protein 
kinase G1; PTK, protein tyrosine kinase; Pak, p21-associated kinase; PDE5, 
phosphodiesterase type 5. Further details are found in the Introduction and Results 
sections. (B) cGMP production by Myh11-Rac1flox/flox vSMC cells pre-treated with indicated 
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chemicals and subsequently stimulated with SNP. EtOH, ethanol; Zap, Zaprinast. *, P ≤ 
0.05 relative to EtOH-treated cells (which express endogenous Rac1) (n = 3).  (C) Amount 
of GTP-RhoA present in Myh11-Rac1flox/flox vSMC cells that were pre-treated with 4OHT 
and stimulated with SNP as indicated. When 4OHT was not added, cells were pre-treated 
with ethanol as above. *, P ≤ 0.05 relative to non-stimulated, EtOH-treated cells or the 
indicated experimental pair (in brackets) (n = 4). (D) Representative immunoblot showing 
the amount of MLC phosphorylation in primary vSMCs from the indicated mice and 
culture conditions (upper panel). Amount of tubulin α was used as loading control (lower 
panel).  Similar results were obtained in two additional independent experiments. (E) 
cGMP production by SNP-stimulated vSMC cells obtained from WT and C-OncoVav2 
mice. When indicated, cells were pre-treated with Zaprinast. *, P ≤ 0.05 relative to SNP-
stimulated WT cells (n = 3). (F and G) Mean arterial pressure present in Myh11-Rac1flox/flox 
(F) and Vav family knockout (G) mice subjected to indicated treatments. Sildenafil was 
added in the drinking water for one week in each case before blood pressure evaluation. **, 
P ≤ 0.01 compared to control mice or the indicated experimental pairs (in brackets) (n = 4 
to 6).  (H and I) Mean arterial pressure present in control (H and I), tamoxifen-treated 
Myh11-Rac1flox/flox (H), and C-OncoVav2 (I) mice that were either untreated (–) or treated 
(+L-NAME) with L-NAME for one week. **, P ≤ 0.01; ***, P ≤ 0.001 compared to either 
the appropriate control mice or indicated experimental pairs (in brackets) (n = 4). N.S., not 
statistically significant. (J and K) Mean arterial pressure present in control (J and K), 
tamoxifen-treated Myh11-Rac1flox/flox (J), and C-OncoVav2 (K) mice upon the systemic 
infusion of AngII for two weeks. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 compared to 
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either the appropriate control mice or indicated experimental pairs (in brackets) (n = 4). 
Error bars in all graphs of this figure represent the S.E.M. 
 
FIGURE 5. Rac1, but not Vav2, is important for vSMC-mediated neointima 
formation. (A and B) Representative images (A; scale bar, 100 µm) and quantification (B) 
of neointima formation in Myh11-Rac1flox/flox mice three weeks after performing the 
tamoxifen-dependent recombination step.  *, P ≤ 0.001 relative to oil-injected mice in the 
same distance interval (n = 4). (C and D) Representative images (C; scale bar, 100 µm) and 
quantification (D) of neointima formation in mice of indicated genotypes (n = 4). In all 
graphs of this figure, error bars represent the S.E.M. (E and F) Representative images (E; 
scale bar, 10 µm) and quantification (F) of the migration of primary Myh11-Rac1flox/flox 
(treated as indicated on left, two top rows of panels), Vav2+/+ (WT, third row of panels from 
top), and Vav2–/– (bottom panels) vSMCs. In E, the experimental time points upon 
performing the wound are indicated on top.  The green fluorescence is from a fluorochrome 
incorporated into cells prior to the wound healing experiment (see Materials and Methods). 
*, P ≤ 0.001 relative to the appropriate control cell culture (n = 3). (G) Platelet-derived 
growth factor-induced proliferation of serum-starved vSMCs of indicated genotypes.  For 
color codes, see inset in panel F. *, P ≤ 0.001 relative to the appropriate control cell culture 
(n = 3). (H) Schematic representation of Rac1-dependent physiological (green color) and 
pathological (red colors) responses triggered by vSMCs.  Upstream exchange factors (GEF) 
are indicated on top. 
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FIGURE 6. vSMC signaling dysfunctions require cross-talk with downstream 
vasopressor mechanisms for hypertension development. (A to E) Evolution of the 
amount of plasma choline (A), serotonin (B), AngII (C), noradrenaline (D), and adrenaline 
(E) in Myh11-Rac1flox/flox mice upon the final injections with either oil or tamoxifen. This 
time point was considered as 0. The periods associated with hypertension conditions (see 
Fig. 2D) are indicated as shaded areas in all panels.  *, P ≤ 0.05; ***P ≤ 0.001 compared to 
oil-injected mice (n = 4). (F) Evolution of the heart rates in same animals and experimental 
conditions. Periods of hypertension are indicated as above. *, P ≤ 0.05; **P ≤ 0.01 
compared to oil-injected mice (n = 4). (G) Plasma glucose concentration upon glucose 
injection in mice two (left panel) and three (right panel) months after final injections with 
either oil or tamoxifen (n = 4 and 5 for oil- and tamoxifen-treated mice, respectively). (H) 
Representative images of hematoxylin-eosin stained sections from indicated tissues (left) 
derived from four-month old Myh11-Rac1flox/flox mice three months upon either the oil or 
tamoxifen injections (top). Scale bars, 100 µm. No signs of steatosis (top panels) or 
hypertrophy of white (middle panels) or brown (bottom panels) adipocytes are seen (n = 4 
and 5 for oil- and tamoxifen-treated mice, respectively). (I) Abundance of indicated 
mRNAs typically associated with hepatic steatosis in livers obtained from four-month old 
mice treated as in G (n = 4 and 5 for oil- and tamoxifen-treated mice, respectively). Error 
bars in graphs of this figure represent the S.E.M. 
 
FIGURE 7. The renin-angiotensin II and sympathetic systems are required to 
maintain the hypertension of Myh11-Rac1flox/flox mice. (A) Summary of the evolution of 
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indicated physiological parameters and regulatory molecules (left) in Myh11-Rac1flox/flox 
mice upon the tamoxifen-induced recombination step in the Rac1 locus (data derived from 
Fig. 6). Upregulated (red boxes on basal lane) and downregulated (blue bloxes underneath 
basal lane) responses are indicated. The time upon the recombination step is indicated at the 
top.  Effects induced by indicated drug treatments on either tamoxifen-treated Myh11-
Rac1flox/flox (column labeled as “Capt”) or wild type (columns labeled as “AngII”, 
“AngII+ARI” and “Atr” in shaded box) mice are also shown (see right box for other 
symbols used in this panel). Capt, captopril; ARI, adrenergic receptor inhibitors; Atr, 
atropine; N.D., not determined. (B) Evolution of mean arterial pressure of tamoxifen-
treated Myh11-Rac1flox/flox mice upon indicated drug treatments. A shaded area indicates the 
time of administration of each drug. As control, we included the mean arterial pressure of 
control, oil-injected Myh11-Rac1flox/flox mice. *, P ≤ 0.05; **, P ≤ 0.01; ***P ≤ 0.001 
relative to oil-injected mice at the indicated experimental time points (n = 4).  (C) Left 
panel, mean arterial pressure of Myh11-Rac1flox/flox mice that, four weeks after the injections 
with tamoxifen, were treated with the indicated drugs for one week. Right panel, mean 
arterial pressure of Myh11-Rac1flox/flox mice treated with the indicated treatments before and 
after being injected with either oil or tamoxifen. Recordings were done one week upon the 
indicated injections. In both cases, we include for comparison the arterial pressure values of 
control mice simply injected with oil.  Sild, sildenafil; Prop, propranolol. **, P ≤ 0.01 
relative to oil-injected mice (n = 4).  In all graphs of this figure, error bars represent the 
S.E.M. 
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